Eli Lilly's continued advancements in pharmaceutical innovation and their commitment to escalating manufacturing capabilities encapsulate the core of the company's recent endeavors. At the heart of these developments is Eli Lilly’s extensive investment in research and development and the subsequent
Johnson & Johnson (J&J) has announced plans to construct a state-of-the-art biologics plant in Wilson, North Carolina, with construction set to commence in the first half of 2025. This ambitious project comes with a substantial investment exceeding $2 billion, aimed at bolstering J&J's supply chain
Cell and gene therapies (C>s) have emerged as revolutionary treatments, particularly for rare diseases with limited treatment options. The rapid growth in demand for these personalized medicines has posed significant challenges for the industry, particularly in maintaining product consistency,
Afton Scientific is making headlines with its substantial investment of over $200 million to expand its biopharmaceutical manufacturing facility in Albemarle County, Virginia. This significant expansion not only highlights the company's commitment to growth but also underscores the robust health of
PCI Pharma Services has made a monumental $365 million investment to enhance its capabilities in the assembly and packaging of sophisticated drug-device combination products, particularly those involving injectable formats. This global Contract Development and Manufacturing Organization (CDMO) aims
The long-term commercial supply agreement between Lonza and Vertex Pharmaceuticals marks a pivotal moment in the field of gene therapy, promising significant advancements for patients suffering from sickle cell disease (SCD) and beta-thalassemia. This collaboration focuses on the production of
